Genmab A/S (GMAB) Stock Chart & Stock Price History → Does this make you sick? (From Allegiance Gold) (Ad) Free GMAB Stock Alerts $28.52 +0.32 (+1.13%) (As of 08:39 AM ET) Add Compare Share Share ChartStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Genmab A/S Stock Price Performance5 Day Performance+1.89%1 Month Performance-4.04%3 Month Performance-2.63%6 Month Performance-10.79%Year-To-Date Performance-10.43%1 Year Performance-27.93% Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter Email Address Ad InvestorPlaceMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… GMAB Stock Chart for Monday, June, 3, 2024 GMAB Chart by TradingView Genmab A/S Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/31/2024$27.99$28.20+0.75%$28.42$27.98479,399 shs$18.65 billion05/30/2024$27.99$27.99$28.16$27.94241,101 shs$18.51 billion05/29/2024$28.01$27.99-0.07%$28.08$27.77400,985 shs$18.51 billion05/28/2024$28.00$28.01+0.04%$28.53$27.90545,901 shs$18.52 billion05/27/2024$28.00$28.00$28.17$27.81594,500 shs$18.51 billion05/24/2024$29.34$28.00-4.57%$28.17$27.81585,227 shs$18.51 billion Get the Latest News and Ratings for GMAB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. 05/23/2024$29.81$29.34-1.58%$29.96$29.13364,201 shs$19.40 billion05/22/2024$29.15$29.81+2.26%$30.06$29.66383,700 shs$19.71 billion05/21/2024$29.69$29.15-1.82%$29.44$29.13335,499 shs$19.27 billion05/20/2024$29.98$29.69-0.97%$30.01$29.63247,010 shs$19.63 billion05/17/2024$29.65$29.98+1.11%$30.00$29.52375,160 shs$19.82 billion05/16/2024$30.22$29.65-1.89%$29.83$29.50587,476 shs$19.61 billion05/15/2024$29.53$30.22+2.34%$30.41$29.73514,376 shs$19.98 billion05/14/2024$29.16$29.53+1.27%$29.53$29.24652,226 shs$19.53 billion05/13/2024$28.84$29.16+1.11%$29.52$28.72688,692 shs$19.28 billion05/10/2024$28.81$28.84+0.10%$28.93$28.71259,970 shs$19.07 billion05/09/2024$28.80$28.81+0.03%$28.94$28.66330,417 shs$19.05 billion05/08/2024$29.29$28.80-1.67%$29.25$28.74592,927 shs$19.04 billion05/07/2024$29.03$29.29+0.90%$29.36$28.89676,857 shs$19.37 billion05/06/2024$29.72$29.03-2.32%$29.29$28.89406,779 shs$19.20 billion05/03/2024$27.72$29.72+7.22%$29.92$29.46718,302 shs$19.65 billion05/02/2024$28.75$27.72-3.58%$28.27$27.42667,528 shs$18.33 billion05/01/2024$27.69$28.75+3.83%$29.00$27.97876,260 shs$19.01 billion04/30/2024$28.57$27.69-3.08%$28.40$27.66933,125 shs$18.31 billion04/29/2024$28.15$28.57+1.49%$28.65$28.01591,815 shs$18.89 billion04/26/2024$27.46$28.15+2.51%$28.18$27.91338,746 shs$18.61 billion04/25/2024$28.47$27.46-3.55%$27.80$27.43436,363 shs$18.16 billion04/24/2024$28.56$28.47-0.32%$28.76$28.09456,119 shs$18.83 billion04/23/2024$28.97$28.56-1.42%$29.04$28.54559,802 shs$18.88 billion04/22/2024$28.70$28.97+0.94%$29.21$28.72452,366 shs$19.16 billion04/19/2024$28.33$28.70+1.31%$28.81$28.45361,029 shs$18.98 billion04/18/2024$28.53$28.33-0.70%$28.62$28.29243,953 shs$18.73 billion04/17/2024$29.43$28.53-3.06%$28.84$28.44358,638 shs$18.86 billion04/16/2024$29.51$29.43-0.27%$29.61$28.77342,399 shs$19.46 billion04/15/2024$29.26$29.51+0.85%$29.67$29.27544,079 shs$19.51 billion04/12/2024$29.74$29.26-1.61%$29.79$29.15413,219 shs$19.33 billion04/11/2024$29.95$29.74-0.70%$30.11$29.42327,641 shs$19.65 billion04/10/2024$29.97$29.95-0.07%$30.12$29.54375,459 shs$19.79 billion04/09/2024$29.86$29.97+0.37%$30.00$29.63385,110 shs$19.80 billion04/08/2024$29.76$29.86+0.34%$29.94$29.67222,156 shs$19.73 billionI’m afraid WWIII is a very real possibility (Ad)As one top U.S. cyber official claims: This [tech] is “the most powerful weapon of our time.” That's also why I've produced this new film.Take a look.04/05/2024$29.65$29.76+0.37%$29.88$29.61237,451 shs$19.66 billion04/04/2024$29.30$29.65+1.19%$30.50$29.63517,560 shs$19.59 billion04/03/2024$29.96$29.30-2.20%$29.68$29.17782,237 shs$19.36 billion04/02/2024$30.27$29.96-1.02%$30.31$29.75281,668 shs$19.80 billion04/01/2024$29.91$30.27+1.20%$30.34$29.70362,330 shs$20.00 billion03/29/2024$29.91$29.91$30.56$29.84361,406 shs$19.76 billion03/28/2024$30.63$29.91-2.35%$30.56$29.84361,389 shs$19.76 billion03/27/2024$30.83$30.63-0.65%$30.63$30.11319,427 shs$20.24 billion03/26/2024$29.98$30.83+2.84%$31.02$30.68538,488 shs$20.37 billion03/25/2024$29.92$29.98+0.20%$30.10$29.89332,598 shs$19.81 billion03/22/2024$29.56$29.92+1.22%$30.27$29.83358,837 shs$19.77 billion03/21/2024$29.44$29.56+0.41%$29.93$29.49369,800 shs$19.53 billion03/20/2024$29.64$29.44-0.67%$29.57$29.28286,675 shs$19.45 billion03/19/2024$29.69$29.64-0.17%$29.68$29.36326,680 shs$19.58 billion03/18/2024$29.94$29.69-0.84%$30.01$29.68411,189 shs$19.62 billion03/15/2024$30.30$29.94-1.19%$30.22$29.691.01 million shs$19.78 billion03/14/2024$31.34$30.30-3.32%$31.26$30.11631,143 shs$20.02 billion03/13/2024$31.43$31.34-0.29%$31.88$31.27368,541 shs$20.71 billion03/12/2024$31.68$31.43-0.79%$31.48$31.05749,959 shs$20.77 billion03/11/2024$30.30$31.68+4.55%$31.81$30.961.22 million shs$20.93 billion03/08/2024$29.41$30.30+3.03%$30.31$29.84492,492 shs$20.02 billion03/07/2024$28.86$29.41+1.91%$29.52$29.23254,754 shs$19.43 billion03/06/2024$28.75$28.86+0.38%$29.19$28.86479,237 shs$19.07 billion03/05/2024$28.51$28.75+0.84%$28.90$28.50618,549 shs$19.00 billion03/04/2024$29.29$28.51-2.66%$28.81$28.39553,391 shs$18.84 billion Related Companies: Takeda Pharmaceutical Stock Chart Teva Pharmaceutical Industries Stock Chart Alnylam Pharmaceuticals Stock Chart Royalty Pharma Stock Chart BioMarin Pharmaceutical Stock Chart BeiGene Stock Chart Viatris Stock Chart Sarepta Therapeutics Stock Chart United Therapeutics Stock Chart Dr. Reddy's Laboratories Stock Chart Receive GMAB Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:GMAB) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldAlert: Your Bank is Dying – Act Now or Lose Everything!Priority GoldNext President (Not Trump. Not Biden.)The Freeport SocietyWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHistoric Crash Could Wipe Away Your 401k (Govt Debt Explosion)Birch GoldPrepare for a Recession Unlike Any OtherAmerican Hartford Gold Group"Trump Loophole" Beats InflationColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.